Cargando…
A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study
PURPOSE: To develop a model for systematic introduction and to test the feasibility in a chronic disease population. We also investigated how the approach was received by the patients. METHODS AND RESULTS: The systematic introduction approach is a seven-step procedure: step 1, define a few main crit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782406/ https://www.ncbi.nlm.nih.gov/pubmed/32820363 http://dx.doi.org/10.1007/s00228-020-02979-w |
_version_ | 1783631895030923264 |
---|---|
author | Norberg, Helena Bergdahl, Ellinor Ängerud, Karin Hellström Lindmark, Krister |
author_facet | Norberg, Helena Bergdahl, Ellinor Ängerud, Karin Hellström Lindmark, Krister |
author_sort | Norberg, Helena |
collection | PubMed |
description | PURPOSE: To develop a model for systematic introduction and to test the feasibility in a chronic disease population. We also investigated how the approach was received by the patients. METHODS AND RESULTS: The systematic introduction approach is a seven-step procedure: step 1, define a few main criteria; step 2, primary scan patients with the one or two main criteria using computerized medical records/databases/clinical registries; step 3, identify patients applying the other predefined criteria; step 4, evaluate if any examinations/laboratory test updates are required; step 5, summon identified patients to the clinic with an information letter; step 6, discuss treatment with the patient and prescribe if appropriate; and step 7, follow up on initiated therapy and evaluate the applied process. The model was tested in a case study during introduction of the new drug sacubitril-valsartan in a heart failure population. In total, 76 out of 1924 patients were identified to be eligible for sacubitril-valsartan and summoned to the clinic to discuss treatment. Patient experiences with the approach were investigated in an interview study with general inductive approach using qualitative content analysis. This resulted in three final categories: a good approach, role of the information letter, and trust in care. CONCLUSIONS: The systematic introduction approach ensures that strict criteria are used in the selection process and that a treatment can be implemented in eligible patients within a specified population with limited resources and time. The model was effective in our case study and maintained the patient’s confidence in healthcare. |
format | Online Article Text |
id | pubmed-7782406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-77824062021-01-11 A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study Norberg, Helena Bergdahl, Ellinor Ängerud, Karin Hellström Lindmark, Krister Eur J Clin Pharmacol Pharmacoepidemiology and Prescription PURPOSE: To develop a model for systematic introduction and to test the feasibility in a chronic disease population. We also investigated how the approach was received by the patients. METHODS AND RESULTS: The systematic introduction approach is a seven-step procedure: step 1, define a few main criteria; step 2, primary scan patients with the one or two main criteria using computerized medical records/databases/clinical registries; step 3, identify patients applying the other predefined criteria; step 4, evaluate if any examinations/laboratory test updates are required; step 5, summon identified patients to the clinic with an information letter; step 6, discuss treatment with the patient and prescribe if appropriate; and step 7, follow up on initiated therapy and evaluate the applied process. The model was tested in a case study during introduction of the new drug sacubitril-valsartan in a heart failure population. In total, 76 out of 1924 patients were identified to be eligible for sacubitril-valsartan and summoned to the clinic to discuss treatment. Patient experiences with the approach were investigated in an interview study with general inductive approach using qualitative content analysis. This resulted in three final categories: a good approach, role of the information letter, and trust in care. CONCLUSIONS: The systematic introduction approach ensures that strict criteria are used in the selection process and that a treatment can be implemented in eligible patients within a specified population with limited resources and time. The model was effective in our case study and maintained the patient’s confidence in healthcare. Springer Berlin Heidelberg 2020-08-21 2021 /pmc/articles/PMC7782406/ /pubmed/32820363 http://dx.doi.org/10.1007/s00228-020-02979-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Pharmacoepidemiology and Prescription Norberg, Helena Bergdahl, Ellinor Ängerud, Karin Hellström Lindmark, Krister A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study |
title | A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study |
title_full | A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study |
title_fullStr | A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study |
title_full_unstemmed | A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study |
title_short | A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study |
title_sort | systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study |
topic | Pharmacoepidemiology and Prescription |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782406/ https://www.ncbi.nlm.nih.gov/pubmed/32820363 http://dx.doi.org/10.1007/s00228-020-02979-w |
work_keys_str_mv | AT norberghelena asystematicapproachforintroductionofnoveltreatmentstoachronicpatientgroupsacubitrilvalsartanasacasestudy AT bergdahlellinor asystematicapproachforintroductionofnoveltreatmentstoachronicpatientgroupsacubitrilvalsartanasacasestudy AT angerudkarinhellstrom asystematicapproachforintroductionofnoveltreatmentstoachronicpatientgroupsacubitrilvalsartanasacasestudy AT lindmarkkrister asystematicapproachforintroductionofnoveltreatmentstoachronicpatientgroupsacubitrilvalsartanasacasestudy AT norberghelena systematicapproachforintroductionofnoveltreatmentstoachronicpatientgroupsacubitrilvalsartanasacasestudy AT bergdahlellinor systematicapproachforintroductionofnoveltreatmentstoachronicpatientgroupsacubitrilvalsartanasacasestudy AT angerudkarinhellstrom systematicapproachforintroductionofnoveltreatmentstoachronicpatientgroupsacubitrilvalsartanasacasestudy AT lindmarkkrister systematicapproachforintroductionofnoveltreatmentstoachronicpatientgroupsacubitrilvalsartanasacasestudy |